-Author name in bold denotes the presenting author
-Asterisk * with author name denotes a Non-ASH member
Clinically Relevant Abstract denotes an abstract that is clinically relevant.

PhD Trainee denotes that this is a recommended PHD Trainee Session.

Ticketed Session denotes that this is a ticketed session.

Marstacimab-hncq for Treatment of Hemophilia A or Hemophilia B

Program: Special-Interest Sessions
Session: ASH-FDA Joint Symposium II: Challenges and Innovations in Rare Diseases in Non-Malignant Hematology
Monday, December 9, 2024, 4:30 PM-6:00 PM

Roma Rajput, MD

CDER/OCHEN/DNH, Food and Drug Administration, Silver Spring, MD

Disclosures: No relevant conflicts of interest to declare.

See more of: ASH-FDA Joint Symposium II: Challenges and Innovations in Rare Diseases in Non-Malignant Hematology
See more of: Special-Interest Sessions
<< Previous Presentation | Next Presentation >>